Synthetic GHRH agonists show promising therapeutic effects across diabetes, heart disease, eye disease, wound healing, and even cancer inhibition in animal models, well beyond their original role of stimulating growth hormone.
5+ therapeutic areasGHRH agonists demonstrated preclinical benefits across diabetes, cardiac repair, eye disease, wound healing, and cancer inhibition — far beyond their original growth hormone-releasing role.
What the researchers found
GHRH agonists of the JI and MR class demonstrated broad therapeutic potential across multiple organ systems in preclinical studies. MR-409 improved pancreatic β-cell proliferation and metabolic function, and facilitated islet engraftment after transplantation in rodents, offering a new approach to diabetes treatment.
In cardiac models, GHRH agonists improved ejection fraction and reduced infarct size in rats, reduced infarct scar in swine, and attenuated cardiac hypertrophy in mice. Notably, while GHRH agonists stimulated cancer cell growth in vitro, they inhibited tumor growth in vivo in xenograft models and downregulated GHRH receptors, suggesting a complex but potentially beneficial relationship with cancer biology.
Why it matters
GHRH agonists represent a class of peptide therapeutics with unusually broad potential applications. Rather than being limited to growth hormone disorders, these peptides interact with GHRH receptors found throughout the body, opening up treatment possibilities for diabetes, heart disease, eye disease, and wound healing. The paradoxical finding that they inhibit tumors in living animals despite stimulating cancer cells in lab dishes adds an intriguing dimension to their safety and therapeutic profile.
How the study worked
This is a narrative review article summarizing the authors' own body of research and related literature on GHRH agonists. The review covers the synthesis and biological evaluation of potent GHRH agonists (JI and MR class), drawing on preclinical studies in rodents and swine models across multiple disease areas including diabetes, cardiac injury, retinopathy, and cancer.
What this study cannot tell us
The therapeutic effects described are almost entirely from preclinical animal studies (rodents and swine), with no human clinical trial data presented. The paradoxical in vitro vs. in vivo cancer findings are not fully explained mechanistically. As a review from the group that developed many of these agonists, there may be selection bias toward favorable results. Translation from animal models to human therapies remains uncertain.
How to read the evidence
This is a narrative review of primarily preclinical (animal) studies. While the breadth of evidence across multiple disease models is impressive, no human clinical trial data are presented, which limits the evidence grade for clinical applicability.
When this study was published
Published in 2019, this review summarizes a body of preclinical work. Some of the therapeutic applications discussed may have advanced toward clinical trials since publication.
The bigger picture
This research highlights a broader trend in peptide therapeutics: hormones originally characterized for a single function often turn out to have widespread effects through receptors distributed across many tissues. GHRH agonists join GLP-1 agonists and other peptides in demonstrating that targeted peptide therapies can address multiple diseases simultaneously, potentially offering advantages over small-molecule drugs with narrower mechanisms of action.
Questions still open
- Why do GHRH agonists stimulate cancer cell growth in lab settings but inhibit tumor growth in living animals, and what does this mean for human safety?
- When will GHRH agonists like MR-409 advance to human clinical trials for diabetes or cardiac repair?
- Could GHRH agonists be combined with existing therapies like GLP-1 agonists for additive benefits in diabetes management?
Common questions
What are GHRH agonists and what do they do beyond releasing growth hormone?
Are GHRH agonists safe if they can stimulate cancer cells in the lab?
Read the original research
Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists.
Endocrinology, 160(7), 1600-1612
Citation
Schally, Andrew V; Zhang, Xianyang; Cai, Renzhi; Hare, Joshua M; Granata, Riccarda; Bartoli, Manuela. (2019). Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists.. Endocrinology, 160(7), 1600-1612. https://doi.org/10.1210/en.2019-00111